Genfit SA Corporation

Genfit SA Corporation

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Contact Details

Office Address

Genfit SA Corporation
Parc Eurasanté, 885, Avenue Eugène Avinée, Loos, FRANCE 59120
Phone: +33-3-20-16-40-00
Fax: +33-3-20-16-40-01

Executives

Chairman and CEO

Jean-Francois Mouney

EVP Finance and Director

Nathalie Huitorel

Business Reviews for Genfit SA Corporation

Related Companies